medigraphic.com
Centro de Investigaciones Regionales Dr. Hideyo Noguchi, Universidad Autónoma de Yucatán

2011, Number 1

<< Back Next >>

Rev Biomed 2011; 22 (1)

Detection of Human Papillomavirus (HPV) in anogenital condyloma from HIV-1 infected cuban men

Blanco-González OA, Soto-Brito Y, Blanco-González B, Acosta-Tabares S, Capó PV, Toledo ME

Language: Spanish
References: 44
Page: 21-30
PDF size: 234.25 Kb.


ABSTRACT

Introduction. In the general HIV-infected population, there are few data on the prevalence and risk factors for anogenital condyloma, precursor lesions for anogenital cancer. In Cuba, there have been few studies about the prevalence of HPV in HIV infected people.
Objective. Detection and typing HPV in anogenital condyloma lesions from Cuban HIV-1 infected men.
Materials and Methods. We studied samples of warts from 30 Cuban patients attending the Instituto Pedro Kouri. HPV DNA was detected using PCR with MY09/11 primers. HPV DNA typing was conducted by hybridization with 32 low and high-risk HPV DNA biotin-labelled probes. Clinic, epidemiologic and immunologic features of these patients were analyzed.
Results. HPV DNA was detected in 100% of the lesions sampled. Associated with the condyloma lesions, HPV 6 and 11 were detected in 19 of 30 cases (63.3%) and 16 of 30 patients (53.3%), respectively. Multiple infections with high-risk HPV types, predominantly HPV 16 (50%) and 18 (43.3%) were observed in 19 samples, with up to 11 different genotypes in the same patient. Condylomas were frequently localized in perianal region. Trichloroacetic acid (80%) was the most used therapy. In patients with a T lymphocyte CD4+ count ‹500 cell/mm3 high-risk HPV types were detected more frequently. This correlation was statistically significant [X2=11.27;RR=28.5;95% IC: 2.6-306.6(p=0.008)].
Conclusions. High and low risk HPV types detection in condylomas from HIV-infected men and T lymphocyte CD4 count should be considered for the monitoring and early detection of anogenital neoplasia. These findings could be a valuable data for follow-up and treatments.


REFERENCES

  1. Silverberg MJ, Chao C, Leyden WA, Xu L, Tang B, Horberg MA, et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS 2009; 23(17):2337-45.

  2. Soto Y. Papovavirus. En: Llop A, Valdés-Dapena MM, Zuazo JL, editores. Microbiolgía y Parasitología Médica. Ciudad de La Habana: Editorial Ciencias Médicas; 2001.p. 60-5.

  3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1):12-9.

  4. Schiffman MH, Castle P. Epidemiologic studies of a necessary causal risk factor: human papillomavirus infection and cervical neoplasia. J Natl Cancer Inst 2003; 95(6):E2.

  5. McLaughlin-Drubin ME, Munger K. Oncogenic activities of human papillomaviruses. Virus Res 2009; 143(2):195-208.

  6. de Villiers EM, Gunst K. Characterization of seven novel human papillomavirus types isolated from cutaneous tissue, but also present in mucosal lesions. J Gen Virol 2009; 90(Pt 8):1999-2004

  7. Arora R, Kumar A, Prusty BK, Kailash U, Batra S, Das BC. Prevalence of high-risk human papillomavirus (HR-HPV) types 16 and 18 in healthy women with cytologically negative Pap smear. Eur J Obstet Gynecol Reprod Biol 2005; 121(1):104-9.

  8. Chopra KF, Tyring SK. The impact of the human inmmunodeficiency virus on the human papillomavirus epidemic. Aech Dermatol 1997; 133(5):629-33.

  9. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human inmmunodeficiency virus infection and acquired inmmunodeficiency syndrome. J Natl Cancer Inst 2000; 92(18):1500-10.

  10. Kiyofumi E. HPV-associated cutaneous lesions. Uirusu 2008; 58(2):173-82.

  11. Gross G, Pfister H. Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts. Med Microbiol Immunol 2004; 193(1):35-44.

  12. Bauer HM, Greer CF, Manos MM. Determination of genital human papillomavirus infection using consensus PCR. En: Herrington CS, McGee JOD, editors. Diagnostic molecular pathology: a practical approach. Oxford, United Kingdom: Oxford University Press; 1992. p. 132-52.

  13. Gravitt PE, Manos MM. Polymerase chain reactionbased methods for the detection of human papillomavirus DNA. IARC Sci Publ 1992; 119:121-33.

  14. Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. Cervicovaginal human papilloma virus infection in human inmmunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. J Natl Cancer Inst 1999; 91(3):226-36.

  15. Tham KM, Chow VT, Singh P, Tock EP, Ching KC, Lim-Tan SK, et al. Diagnostic sensitivity of polymerase chain reaction and Southern blot hybridization for the detection of human papillomavirus DNA in biopsy specimens from cervical lesions. Am J Clin Pathol 1991; 95(5):638-46.

  16. Zur Hausen H. Papillomaviruses--to vaccination and beyond. Biochemistry 2008; 73(5):498-503.

  17. Bouwes Bavinck JN. Epidemiological aspects of immunosuppression: role of exposure to sunlight and human papillomavirus on the development of skin cancer. Hum Exp Toxicol 1995; 14(1):98.

  18. Bachmeyer C, Orlandin V, Grimaldi D, Bonnard P, Moguelet P, Aractingi S. Skin lesions as another possible clinical manifestation of mitochondrial toxicity in an HIV-infected patient. Dermatology 2007; 214(2):189-90.

  19. Potthoff A, Brockmeyer NH. HIV-associated Kaposi sarcoma: pathogenesis and therapy. J Dtsch Dermatol Ges 2007; 5(12):1091-4.

  20. Stier EA, Baranoski AS. Human papillomavirusrelated diseases in HIV-infected individuals. Curr Opin Oncol 2008; 20(5):541-6.

  21. Palefsky JM, Holly EA, Ralston ML, Da Costa M, Greenblatt RM. Prevalence and risk factors for anal human papillomavirus infection in human inmmunodeficiency virus (HIV)-positive and high-risk HIV-negative women. J Infect Dis 2001; 183(3):383-91.

  22. Palefsky JM. Anal cancer prevention in HIV-positive men and women. Curr Opin Oncol 2009; 21(5):433-8

  23. Hong SL, Wang JB, Liu YH, Si JY, Xu XM, Guo XC, et al. Identification and assessment of multiple human papillomavirus types in condyloma acuminata lesions from patients with genital warts in Beijing area. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2002; 24(4):397-400.

  24. Dupin N. Genital warts. Clin Dermatol 2004; 22(6):481-6.

  25. Corbalan-Velez R, Ruiz-Macia JA, Brufan C, Carapeto FJ. Cutaneous squamous cell carcinoma and human papillomavirus. Actas Dermosifiliogr 2007; 98(9):583-93.

  26. Sexually trasmitted dideases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51(RR-6):1-78.

  27. Ekstrom J, Foeslund O, Dillner J. Three novel papillomaviruses (HPV109,HPV112 and HPV114) and their presence in cutaneous and mucosal samples. Virology 2010; 397(2):331-6.

  28. Shimizu M, Adachi A, Zheng S, Matsunaga J, Kusakari Y, Tagami H, et al. Detection of various types of human papillomavirus DNA, mainly belonging to the cutaneous-group, more frequently in normal tissue than in squamous cell carcinomas of the lip. J Dermatol Sci 2004; 36(1):33-9.

  29. Ljubojevic S, Lipozencic J, Skerlev M, Zele-Starcevic L, Ljubojevic N, Babic D, et al. Diagnostic-therapeutic guidelines for men whose partners have HPV genital infection. Lijec Vjesn 2009; 131(9-10):269-74.

  30. Arany I, Tyring SK. Systemic immunosuppression by HIV infection influences HPV transcription and thus local immune responses in condyloma acuminatum. Int J STD AIDS 1998; 9(5):268-71.

  31. Hessol NA, Holly EA, Efird JT, Minkoff H, Schowalter K, Darragh TM, et al. Anal intraepithelial neoplasia in a multisite study of HIV-infected and high-risk HIV-uninfected women. AIDS 2009; 23(1):59-70.

  32. Trottier H, Burchell AN. Epidemiology of mucosal human papillomavirus infection and associated diseases. Public Health Genomics 2009; 12(5-6):291-307.

  33. O´Mahony C. Genital warts: current and future management options. Am J Clin Dermantol 2005; 6(4):239-43.

  34. Steinberg JL, Cibley LJ, Rice PA. Genital warts: diagnosis, treatment, and counseling for the patient. Curr Clin Top Infect Dis 1993; 13:99-122.

  35. Slade HB, Owens ML,Tomai MA, Miller RL.Imiquimod 5% cream (Aldara). Expert Opin Investig Drugs 1998; 7(3):437-49.

  36. Hober D, Ajram L, Chehadeh W, Lazrek M, Goffard A, Dewilde A, et al. Mechanisms of imiquimod indirect antiviral activity. Ann Biol Clin 2005; 63(2):155-63.

  37. Matezak E. Human papillomavirus infection: an emerging problem in anal and other squamous cell cancers. Gastroenterology 2001; 120(4):1046-8.

  38. Sobhani I, Vuagnat A, Walker F, Vissuzaine C, Mirin B, Hervatin F, et al. Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals. Gastroenterology 2001; 120(4):857-66.

  39. Stanley MA, Immune responses to human papilloma viruses. Indian J Med Res 2009; 130(3):266-76.

  40. Georgieva S, Iordanov V, Sergieva S. Nature of cervical cancer and other HPV - associated cancers. J BUON 2009; 14(3):391-8.




2020     |     www.medigraphic.com